Instil Bio (TIL) Cash & Equivalents (2020 - 2026)

Instil Bio's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 67.32% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (down 67.32% YoY), while the FY2025 annual figure was $6.6 million, down 24.61% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.0 million, down from $6.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $61.5 million in Q1 2022, with the low at $5.0 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $9.1 million (2023), against an average of $19.1 million.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents tumbled 92.51% in 2022, then surged 180.2% in 2025.
• Instil Bio's Cash & Equivalents stood at $43.7 million in 2022, then slumped by 78.97% to $9.2 million in 2023, then fell by 4.24% to $8.8 million in 2024, then slipped by 24.61% to $6.6 million in 2025, then declined by 24.34% to $5.0 million in 2026.
• Business Quant data shows TIL's Cash & Equivalents at $5.0 million in Q1 2026, $6.6 million in Q4 2025, and $5.8 million in Q3 2025.